| |
|
| |
| Links: |
Cyclin-dependent kinase inhibitor function as tumor suppressor proteins by inhibiting the enzyme cyclin-dependent kinase. The enzyme cyclin-dependent kinase controls cell cycle progression, transcription, mRNA processing, and differentiation. Cyclin-dependent kinase inhibitor arrest cell cycle at the G1 phase leading to mitosis. Cyclin-dependent kinase inhibitors are employed in the treatment of cancers by preventing over proliferation of cancer cells. Cyclin-dependent kinase are very active in most cancers which is rational to the use of cyclin-dependent kinase inhibitor as anti-cancer agents.
Cyclin-Dependent Kinase Inhibitor Market: Drivers and Restraints
The growing demand generated due to increasing incidence of cancers owing to increasing exposure to risk factors such as carcinogens, sedentary lifestyles, substance abuse, pollution and others is driving a large market. According to the national cancer institute, prostate cancer accounted for 164,690 new cases in 2018 accounting for 9.5 % of all new cancer cases. The American Cancer Society’s estimates that about 63,340 new cases of kidney cancer are likely to occur in the United States in 2018. The estimates for bladder cancer are about 81,190 new cases likely to occur in the United States in 2018. The growing geriatric population provides a strong impulse for the growth of the cyclin-dependent kinase inhibitor market. The number of people aged 60 years or older is expected to rise from 900 million to 2 billion between 2015 and 2050, representing a growth from 12% to 22% of the total global population, according to recent World Health Organization report. Thus a large cyclin-dependent kinase inhibitor market is well evident even to an untrained eye.
A strong developmental pipeline is another driver of the market. There are more than 10 cyclin-dependent kinase inhibitors under clinical trials of which Trilaciclib shows great promise.
However the constraints such as high cost of treatment, and nascent stage of technology owing to poor understanding of cell cycle is hampering the cyclin-dependent kinase inhibitor market. The poor selectivity of cyclin-dependent kinase inhibitor is another hindrance to their adoption.
Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8708
Cyclin-Dependent Kinase Inhibitor Market: Segmentation
To gain a bird’s eye view of the global cyclin-dependent kinase inhibitor market, the report is segmented on the spectrum, valve type, and region.
Based on the spectrum, the global cyclin-dependent kinase inhibitor market can be segmented as,
Based on the formulation, the global Cyclin-Dependent Kinase Inhibitor market can be segmented as,
Cyclin-Dependent Kinase Inhibitor Market: Regional Wise Outlook
The global cyclin-dependent kinase inhibitor market can be classified into the following region: North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America, led by the U.S., is expected to drive the largest market share owing to the large incidence of cancer, attractive reimbursement large healthcare expenditure, and large per capita income.
The Asia Pacific cyclin-dependent kinase Inhibitor market excluding Japan is projected to expand and dominate the scene in the near future, owing to the growing healthcare.
China and India are anticipated to account for the major share of the Asia Pacific cyclin-dependent kinase inhibitor market growth. Germany, France and the U.K., are projected to be the largest drivers of the Europe cyclin-dependent kinase inhibitor market. The Middle East and Africa cyclin-dependent kinase inhibitor market is anticipated to be dominated by the gulf economies of Saudi Arabia, Kuwait, UAE and Qatar.
Request to View TOC @ https://www.futuremarketinsights.com/toc/rep-gb-8708
Cyclin-Dependent Kinase Inhibitor Market: Market Participants
Some of the major vendors operating in the global cyclin-dependent kinase inhibitor market are Eli Lilly and Company, Pfizer Inc., Novartis, Astex Pharmaceuticals, Merck KGaA, R&D Systems, Inc. and others.
(Added: Wed Feb 13 2019 Hits: 1 Rating: 0.00 Votes: 0) Rate ItIt has been reported that the brain slowly deteriorates as a person ages with the senses, memory and cognitive thinking abilities being affected the most. The deterioration of functions of the brain was explained by the loss of brain plasticity. Brain plasticity is the capacity of the nervous system to change its neural structure in reaction to environmental challenges. However research conducted in the last few years revealed that the brain retains the ability undergoe changes in size and shape in response to stimulation. Brain fitness is an umbrella term for techniques and strategies such as mental and cognitive training, neuroplasticity, neurogenesis, brain vascularization and others which are useful in keeping the brain fit. These are a set of mental exercises to sharpen the senses, memory and attention.
Brain Fitness Market: Drivers and Restraints
The burgeoning demand for brain fitness generated owing to increasing incidence of ADHD, learning disorders, memory loss, brain injury and others is driving a large market. According to the The A.D.D. Resource Center, Inc., 12.9 percent of men and 4.9 percent of women will be diagnosed with the attention disorder at some points in their lifetimes, with the prevalence of attention disorder being 4 percent of American adults over the age of 18. The American Psychiatric Association estimates that 5% of children have ADHD, while the Centers for Disease Control and Prevention (CDC) estimates that 11% of U.S. children aged 4 to 17 suffer from ADHD.
The growing ageing population is another driver of the market. The number of people aged 60 years or older is expected to rise from 900 million to 2 billion between 2015 and 2050, representing a growth from 12% to 22% of the total global population, according to recent World Health Organization report. The prosperous baby boomer population of U.S. is another driver for the market owing to their desire to delay dementia and mental disorders. Thus a large market is well evident.
However the constraints such as lack of awareness, lack of experimental validation regarding the effectiveness and efficacy of the brain fitness therapy and opposition to clinical acceptance is hampering the brain fitness market. Actions by regulatory bodies such as the United States Federal Trade Commission (FTC) which sued companies selling "brain training" programs such as WordSmart Corporation and LearningRx, for deceptive advertising in 2015 is the greatest threat to the market.
Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8709
Brain Fitness Market: Segmentation
To gain a bird’s eye view of the global brain fitness market, the report is segmented on the type, product, end users and region.
Based on the type, the global brain fitness market can be segmented as,
Based on the product, the global brain fitness market can be segmented as,
Based on the end users, the global brain fitness market can be segmented as,
Brain Fitness Market: Regional Wise Outlook
The global brain fitness market can be classified into the following region: North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, and Middle East and Africa. North America, led by the U.S., is expected to drive the largest market share owing to the large incidence of neurological disorders,, ageing baby boomer population and large per capita income.
The Asia Pacific brain fitness market excluding Japan is anticipated to grow owing to the growing awareness and rising incomes. China and India are projected to lead the Asia Pacific brain fitness market growth. Germany, France and the U.K., are projected to be the largest drivers of the Europe brain fitness market. The Middle East and Africa brain fitness market is expected to be led by the gulf economies of Saudi Arabia, Kuwait, UAE and Qatar owing to their large wealth.
Request to View TOC @ https://www.futuremarketinsights.com/toc/rep-gb-8709
Brain Fitness Market: Market Participants
Some of the major vendors operating in the global brain fitness market are AttenGo Ltd., Nintendo, CogniFit , NEEURO, PTE LTD, Synaptikon GmbH, BrainTrain, SMARTfit Inc., Applied Cognitive Engineering,BrainHQ, Lumos Labs, Inc., Total Brain Health, Advanced Brain Technologies, Cogstate, Cogmed, CNS Vital Signs, Lexia Learning, MyBrainTrainer, NovaVision, and others.
(Added: Tue Feb 12 2019 Hits: 2 Rating: 0.00 Votes: 0) Rate ItGrowing use of antibiotics in treating even the most common health conditions remains a strong factor boosting demand for antibiotic susceptibility testing (AST). Increasing government funds for microbial and antibiotic susceptibility testing research and consistently improving outcome of PPPs in terms of enhanced screening and evaluation of antibiotics are playing a pivotal role in strengthening the performance of antibiotic susceptibility testing market. CDC’s 'AMR Challenge' involving bioMérieux is a recently announced as objective to accelerate research efforts in the field of microbial resistance.
A recently published research intelligence on the global antibiotic susceptibility testing market by Future Market Insights tracks the top five influencers pushing demand and revenue growth of the market at a global level.
Infectious diseases, prevailing at a high pace
Increasing rate and tenure of hospitalization
Growing significance of early diagnostics
Soaring research interests in microbial susceptibility testing
Improving funding scenario for research, driven by governments & private bodies
Towards 2019, global revenue through total installed base of antibiotic susceptibility testing systems is likely to see 6.4% yearly growth over that achieved in 2018.
Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8574
Entry of Technologically Advanced AST Systems to Favor Market Growth
As indicated by research, the sales of antibiotic susceptibility testing equipment will witness healthy growth owing to increasing demand for specific susceptibility testing systems to define the scope of targeted therapy. Targeting key pathogens is imperative to design a highly specific plan of treatment for a particular patient, and antibiotic susceptibility testing systems efficiently allow researchers to achieve it within a significantly short timeline.
With FDA approving a considerable number of antibiotic and microbial susceptibility testing equipment, especially in the recent past, FMI forecasts an impressive installed base for antibiotic susceptibility testing systems in coming years. Advanced technology enabled antibiotic susceptibility testing equipment allows early diagnosis that in turn improves chances of developing targeted therapy earlier. One such recent advancement enjoying visibly growing traction in market includes oCelloScope. This antibiotic susceptibility testing equipment by BioSense Solutions is an optical susceptibility screening system with the capability to deliver real-time, time-lapse imaging of multiple microbial combinations, simultaneously.
Recently, Thermo Fisher Scientific, Inc. and Becton, Dickinson and Company received FDA approvals for their new launches in antibiotic susceptibility testing space. Moreover, FDA passed an approval to a susceptibility testing device by bioMérieux that has an expanded capability to identify a particular pathogen.
Research in Screening of High Pathogen Concentration Samples to Propel Demand for AST
The process of spotting a specific set of genes responsible for antibiotic resistance is highly complicated when it comes to handling the complexities associated with samples that have high concentration of pathogens. Some of the highly desirable antibiotic susceptibility testing systems that allow direct-from-sample pathogen identification through high pathogen concentration samples, are thus likely to gain high traction in coming years.
Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-8574
Growing research efforts in the recognition of the presence of a specific set of antibiotic resistant genes can direct efforts for identification and selection of narrow-spectrum antibiotics, which remains among the most prominent factors pushing installed base of such antibiotic susceptibility testing equipment. A few recent launches in this segment include Genmark Diagnostics’ ePLEX Blood Culture ID Panel, Biomerieux’s BioFire FilmArray, and Luminex Corp.’s Verigene Bloodstream Infection Panel.
The report also sheds light on the increasing role of Ecommerce in the market by boosting the availability of antibiotic susceptibility testing systems. Offering improved access to susceptibility testing devices by industry’s leading brands, online retail operators have been attracting prominent vendors in the global antibiotic susceptibility testing market. A number of vendors dealing in antibiotic susceptibility testing equipment are opting for devices that are available online owing to the significantly reduced costs and additional discounts on price.
(Added: Mon Feb 11 2019 Hits: 2 Rating: 0.00 Votes: 0) Rate ItPages: [<<] ... 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 ... [>>]
Links SQL By: Gossamer Threads Inc.